Search Results - "Evans, T.R.J."

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT] by Finn, R.S., Kudo, M., Cheng, A.-L., Wyrwicz, L., Ngan, R., Blanc, J.F., Baron, A.D., Vogel, A., Ikeda, M., Piscaglia, F., Han, K.-H., Qin, S., Minoshima, Y., Kanekiyo, M., Ren, M., Dairiki, R., Tamai, T., Dutcus, C.E., Funahashi, Y., Evans, T.R.J.

Get full text

Developing histone deacetylase inhibitors as anti-cancer therapeutics by Venugopal, B, Evans, T R J

“…Post translational modification of histones and non-histone proteins by acetylation play a key role in tumourigenesis. Histone deacetylases (HDACs) are enzymes…”
Get more information

Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC) by Finn, R.S., Kudo, M., Cheng, A-L., Wyrwicz, L., Ngan, R., Blanc, J-F., Baron, A.D., Vogel, A., Ikeda, M., Piscaglia, F., Han, K-H., Qin, S., Minoshima, Y., Funahashi, Y., Ren, M., Dairiki, R., Sachdev, P., Tamai, T., Dutcus, C., Evans, T.R.J.

Get full text

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer by Evans, T.R.J., Van Cutsem, E., Moore, M.J., Bazin, I.S., Rosemurgy, A., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., Elekes, A., Rock, E., Lin, C., Strauss, L., O’Dwyer, P.J.

“…Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate with limited treatment options. Gemcitabine provides a marginal survival benefit for patients…”
Get full text

The integrin αvβ6 is a promising therapeutic target for treating PDAC by Marshall, John, Vallath, S, Reader, C, Morton, J, Sansom, O, Evans, T.R.J, Biankin, A, Kocher, H.M

Get full text

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours by Macpherson, I.R, Poondru, S, Simon, G.R, Gedrich, R, Brock, K, Hopkins, C.A, Stewart, K, Stephens, A, Evans, T.R.J

“…Abstract Aim To determine the maximum tolerated dose (MTD) of OSI-930 that can be combined with erlotinib, and establish recommended phase 2 doses when both…”
Get full text

599 Effect of Food On Relative Bioavailability of E7820 in Cancer Patients by Slater, S, Witteveen, P.O, Plummer, R, Kristeleit, R, Evans, T.R.J, Reyderman, L, de las Heras, B, Verbel, D, Ink, B, Schellens, J.H.M

Get full text

610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma by Soria, J.C, Plummer, R, Ranson, M, Gan, H, Arkenau, H.T, Zalcman, G, Blagden, S, Evans, T.R.J, Peddareddigari, V, Mazumdar, J, Murray, S, Gibson, D, Fleming, R.A, Auger, K, Millward, M

Get full text

613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors by Gan, H, Nebot, N, Soria, J.C, Arkenau, H.T, Blagden, S, Plummer, R, Ranson, M, Evans, T.R.J, Zalcman, G, Peddareddigari, V, Gibson, D, Murray, S, Mazumdar, J, Fleming, R, Auger, K, Millward, M

Get full text

6590 POSTER Phase Ma Study of TP300 as 1st-line Monotherapy in Patients With Advanced Gastric (GC) or Gastro-oesophageal Junction (GOJ) Carcinoma by Evans, T.R.J, Propper, D.J, Anthoney, D.A, Mansoor, W, Eatock, M.M, Ford, D, Agarwal, R, Thomson, D, Miwa, M

Get full text

mTOR signaling is a promising therapeutic target in a subset of human pancreatic ductal adenocarcinomas by Morran, D.C, Karim, S.A, Jamieson, N.B, McKay, C.J, Carter, R, Evans, T.R.J, Sansom, O.J, Morton, J.P

“…Category: Malignant Purpose: Human pancreatic ductal adenocarcinoma (PDAC) remains an intractable disease with little change in 5 year survival over the past…”
Get full text

CXCR2 inhibition protects against chronic pancreatitis in a murine model by Steele, C.W, Morton, J.P, McKay, C.J, Evans, T.R.J, Carter, C.R, Sansom, O.J

“…To examine the importance of neutrophils in this process we used a neutrophil blocking antibody and found that there was significant pancreatic damage from…”
Get full text

123 Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action by Barnett, A, Ding, S, Murray, C, Chamberlain, M, Plummer, S, Evans, T.R.J, MacPherson, I, Bissett, D, Elcombe, C.R, Wolf, C.R

Get full text

391 A phase I clinical trial of CXR1002 in patients (pts) with advanced cancer by Macpherson, M, Bissett, D, Tait, B, Samuel, L.M, MacDonald, J, Barnett, A.L, Wolf, C.R, Elcombe, C.R, Jeynes-Ellis, A, Evans, T.R.J

Get full text

1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma by Shoushtari, A.N., Middleton, M.R., Hamid, O., Meier, F., Bauer, T., Salama, A.K.S., Kirkwood, J.M., Ascierto, P.A., Lorigan, P., Mauch, C., Orloff, M., Edukulla, R., Goodall, H., Hassel, J.C., Evans, T.R.J.

Get full text

LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes by Wasan, H.S., Wang, J., Elaine McCartney, E.M., Soifer, H., Treuner, K., Zhang, Y., Schnabel, C., K. Carty, McMahon, L., Evans, T.R.J., Nicolson, M.C., Thygesen, H., Roche, J.R., Oien, K.A.

Get full text

549P Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301) by Spiliopoulou, P., Kazmi, F., Aroldi, F., Holmes, J., Graham, J., Holmes, T., Lord, S., Veal, G., Qi, C., Coyle, V.M., Evans, T.R.J., Blagden, S.

Get full text

527P Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM) by Sarker, D., Evans, T.R.J., Van Cutsem, E., Prenen, H., Middleton, M.R., Bhoi, S., Tunblad, K., Oberg, F., Morris, T., Plummer, R.

Get full text

475P A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302) by Berlin, J., Coveler, A.L., Ciombor, K.K., Kazmi, F., Graham, J., Peters, M.L., Clark, J.W., Myers, M., De Gramont, A., Evans, T.R.J., Blagden, S.

Get full text

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors by Soria, J.C., Gan, H.K., Blagden, S.P., Plummer, R., Arkenau, H.T., Ranson, M., Evans, T.R.J., Zalcman, G., Bahleda, R., Hollebecque, A., Lemech, C., Dean, E., Brown, J., Gibson, D., Peddareddigari, V., Murray, S., Nebot, N., Mazumdar, J., Swartz, L., Auger, K.R., Fleming, R.A., Singh, R., Millward, M.

“…This paper presents results from the phase I study of the focal adhesion kinase inhibitor GSK2256098 in patients with advanced solid tumors. The MTD was…”
Get full text